Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT02963779 | A Study of LY2775240 in Healthy Participants | PHASE1 | COMPLETED | 35 | — | — | Dec 1, 2016 | Oct 5, 2017 | Nov 7, 2017 | 1 | Singapore |
| Arm | Type | Description |
|---|---|---|
| LY2775240 (Part A) | EXPERIMENTAL | Escalating oral doses of LY2775240 administered in healthy participants |
| LY2775240 (Part B) | EXPERIMENTAL | Oral dose of LY2775240 in healthy participants |
| Placebo (Part A) | PLACEBO_COMPARATOR | Placebo administered orally in healthy participants |
| Apremilast (Part B) | ACTIVE_COMPARATOR | Oral dose of apremilast in healthy participants |
| Name | Type | Description |
|---|---|---|
| LY2775240 | DRUG | Administered orally |
| Placebo | DRUG | Administered orally |
| Apremilast | DRUG | Administered orally |
Inclusion Criteria: * Overtly healthy adult male or a female who cannot get pregnant * Have a screening body mass index (BMI) of greater than 18 and less than or equal to 32 kilograms per meter square (kg/m²), inclusive * Have normal blood pressure, pulse rate, electrocardiogram (ECG) and medical t...